ClinicalTrials.gg
RecruitingNCT06728436CuidaTEXT R01Updated Nov 9, 2026

Testing the Effects of a Text Message Caregiver Support Intervention for Latinos

An interventional study of CuidaTEXT in Alzheimer Disease, sponsored by University of Kansas Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University of Kansas Medical Center · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
288
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Alzheimer Disease by University of Kansas Medical Center — 3 open to participants now, 4 under way, none of them phase 3. Alzheimer Disease · University of Kansas Medical Center.

Planned enrollment
2nd of 16
288 · median 71
Started
2025
the only one that year
No phase
16 of 20
3 open now
Registered
19th of 20
by date

Among the 20 studies in Alzheimer Disease by University of Kansas Medical Center, this one is the 2nd largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2025, is one of 16 with no phase, and was the 19th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

3 of the 20 studies in Alzheimer Disease by University of Kansas Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Alzheimer Disease by University of Kansas Medical Center, or all of them as a file.
02

Study summary

The goal of this randomized clinical trial it to test the efficacy of CuidaTEXT, the first Alzheimer's disease and Related Dementias (ADRD) caregiver support intervention to capitalize on text messaging, among Latinos.

Researchers will compare those who receive the CuidaTEXT intervention to those who do not receive the intervention to see if CuidaTEXT effects Latino caregiver stressors and their negative consequences .

Participants will receive a variety of text messages, from automatic to keyword-drive, regarding ADRD education, social support, self-care, ADRD care management, and behavioral symptoms. Participants will also complete measures regarding depressive symptoms, coping, behavioral symptoms, and preparedness for caregiving.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over the age of 18
  • Spanish and English-speaking people who identify as Latino
  • Reports providing hands-on care for a relative who has been given a clinical or research ADRD diagnosis and has an Eight-item Informant Interview to Differentiate Aging and Dementia (AD-8) screening score ≥2, indicating cognitive impairment
  • Has a score of 7 or higher on the 10-item Center for Epidemiologic Studies Depression Scale (CESD-10)
  • Self-reports being able to read and write
  • Owns a cell phone with a flat fee, and uses it at least weekly for texting.

Exclusion criteria

Exclusion Criteria:

  • Participation in another wellbeing-related clinical trial
  • Cohabitation with another participant in the CuidaTEXT R01 Study
  • Participants who provide care for a person with ADRD already cared for by another participant in the CuidaTEXT R01 study
  • Participant plans to move to another country within seven months
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
288 participants (estimated)

Study arms

  • Experimental
    CuidaTEXT

    6 months of CuidaTEXT intervention + 1-month post-treatment

    Behavioral: CuidaTEXT

  • No intervention
    7-Month Waitlist Control

    Participants allocated to this arm will be offered the opportunity to start CuidaTEXT immediately after their 7 Month follow-up assessment

Interventions

  • BehavioralCuidaTEXT

    CuidaTEXT is a multidomain, bilingual 6-month text message intervention that includes delivery and content features tailored to Latino caregivers. All caregivers receive one core daily automatic message on five domains: ADRD education, social support, self-care, ADRD care management, and behavioral symptoms. Caregivers can access on-demand automatic messages to expand on the five domains via sending keywords and interact with a coach via a live chat for more personalized help.

06

What researchers measure

Primary outcomes

  1. Change in caregiver depressive symptoms

    Change in caregiver depressive symptoms from baseline to 6 months as measured by the 10-item Center for Epidemiologic Studies Depression Scale (CESD-10). The CES-D-10 is a self-report rating scale that measures characteristic symptoms of depression in the past week (e.g. depression, loneliness). Each item is rated on a 4-point scale (Rarely or None of the Time-Most or All of the Time). The summary score ranges from 0 to 30 with higher scores indicating higher severity.

    Time frame: Baseline and 6 months

Secondary outcomes

  1. Change in caregiver behavioral distress symptoms

    Change in caregiver behavioral distress symptoms from baseline to 6 months as measured by the Neuropsychiatric Inventory-Questionnaire (NPI-Q).If any of 12 care recipient behavioral symptoms is present in the last month (e.g., repeating, delusions), caregivers rate their own distress on a 6-point scale (Not at All-Extreme). A distress summary score is calculated by adding the scores of all items, with scores ranging from 0 to 60. Higher scores indicate higher distress.

    Time frame: Baseline and 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Perales-Puchalt J, Ramirez-Mantilla M, Moore HP, Velez-Uribe I, Sepulveda-Rivera V, Ruiz R, Fracachan-Cabrera M, Herrera Y, Baker C, Miras-Neira A, Bothwell B, Anderson H, Lewandowski T, Diaz FJ, Greiner KA, Williams K, Vidoni ED, Ellerbeck E, Burns JM. Testing the effects of a text message intervention on depression and distress among Latino dementia caregivers: a randomized controlled trial protocol. medRxiv [Preprint]. 2025 Sep 18:2025.09.16.25335909. doi: 10.1101/2025.09.16.25335909. PubMed 41001476 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for May 2029, 51 months after the start.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 51 months is above that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2024
First posted
Dec 11, 2024
StartActual
Feb 17, 2025
Primary completionEst.
May 2029
CompletionEst.
May 2029
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06728436
Responsible party
Jaime Perales Puchalt, PhD, MPH (Assistant Professor, University of Kansas Medical Center) — Principal investigator
First posted
Dec 11, 2024
Start date
Feb 17, 2025
Primary completion
May 2029 (estimated)
Completion
May 2029 (estimated)
Last update
Nov 9, 2026

Study contacts

Rachel Ruiz
Contact
rruiz3@kumc.edu
913-945-5052
Jaime Perales Puchalt, PhD, MPH
Contact
jperales@kumc.edu
913-588-3716
Jaime Perales Puchalt, PhD, MPH
principal investigator · University of Kansas Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion